PeptiDream Inc.

TSE:4587 Stock Report

Market Cap: JP¥330.5b

PeptiDream Valuation

Is 4587 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4587 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4587 (¥2547) is trading below our estimate of fair value (¥3088.14)

Significantly Below Fair Value: 4587 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4587?

Key metric: As 4587 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4587. This is calculated by dividing 4587's market cap by their current earnings.
What is 4587's PE Ratio?
PE Ratio19.3x
EarningsJP¥17.11b
Market CapJP¥330.51b

Price to Earnings Ratio vs Peers

How does 4587's PE Ratio compare to its peers?

The above table shows the PE ratio for 4587 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average48.1x
2160 GNI Group
19.4x23.4%JP¥141.9b
4974 Takara Bio
141.9x25.2%JP¥129.8b
2929 Pharma Foods International
8.4xn/aJP¥27.6b
177A Kohjin Bio
22.7x25.7%JP¥9.1b
4587 PeptiDream
19.3x-9.0%JP¥330.5b

Price-To-Earnings vs Peers: 4587 is good value based on its Price-To-Earnings Ratio (19.3x) compared to the peer average (48.1x).

Price to Earnings Ratio vs Industry

How does 4587's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
4587 19.3xIndustry Avg. 32.6xNo. of Companies11PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4587 is good value based on its Price-To-Earnings Ratio (19.3x) compared to the Asian Biotechs industry average (32.6x).

Price to Earnings Ratio vs Fair Ratio

What is 4587's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4587 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.3x
Fair PE Ratio16x

Price-To-Earnings vs Fair Ratio: 4587 is expensive based on its Price-To-Earnings Ratio (19.3x) compared to the estimated Fair Price-To-Earnings Ratio (16x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4587 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥2,547.00
JP¥3,364.29
+32.1%
19.7%JP¥4,900.00JP¥2,700.00n/a7
Nov ’25JP¥2,700.00
JP¥3,350.00
+24.1%
19.9%JP¥4,900.00JP¥2,700.00n/a7
Oct ’25JP¥2,729.00
JP¥3,342.86
+22.5%
20.0%JP¥4,900.00JP¥2,700.00n/a7
Sep ’25JP¥2,560.00
JP¥3,366.67
+31.5%
21.4%JP¥4,900.00JP¥2,700.00n/a6
Aug ’25JP¥2,690.00
JP¥3,250.00
+20.8%
24.5%JP¥4,900.00JP¥2,500.00n/a6
Jul ’25JP¥2,423.00
JP¥2,883.33
+19.0%
34.9%JP¥4,900.00JP¥1,900.00n/a6
Jun ’25JP¥1,969.00
JP¥2,850.00
+44.7%
35.0%JP¥4,900.00JP¥1,900.00n/a6
May ’25JP¥2,081.00
JP¥2,666.67
+28.1%
42.6%JP¥4,900.00JP¥1,400.00n/a6
Apr ’25JP¥1,426.00
JP¥2,666.67
+87.0%
42.6%JP¥4,900.00JP¥1,400.00n/a6
Mar ’25JP¥1,533.50
JP¥2,733.33
+78.2%
40.3%JP¥4,900.00JP¥1,400.00n/a6
Feb ’25JP¥1,256.00
JP¥2,750.00
+118.9%
40.6%JP¥4,900.00JP¥1,400.00n/a6
Jan ’25JP¥1,486.50
JP¥2,733.33
+83.9%
41.6%JP¥4,900.00JP¥1,300.00n/a6
Dec ’24JP¥1,264.00
JP¥2,733.33
+116.2%
41.6%JP¥4,900.00JP¥1,300.00n/a6
Nov ’24JP¥1,126.00
JP¥2,766.67
+145.7%
41.5%JP¥4,900.00JP¥1,300.00JP¥2,700.006
Oct ’24JP¥1,611.00
JP¥3,060.00
+89.9%
33.7%JP¥4,900.00JP¥1,900.00JP¥2,729.005
Sep ’24JP¥1,858.00
JP¥3,050.00
+64.2%
30.9%JP¥4,900.00JP¥1,900.00JP¥2,560.006
Aug ’24JP¥1,829.00
JP¥3,066.67
+67.7%
30.9%JP¥4,900.00JP¥1,900.00JP¥2,690.006
Jul ’24JP¥2,140.00
JP¥3,116.67
+45.6%
28.5%JP¥4,900.00JP¥2,200.00JP¥2,423.006
Jun ’24JP¥2,298.00
JP¥3,116.67
+35.6%
28.5%JP¥4,900.00JP¥2,200.00JP¥1,969.006
May ’24JP¥1,827.00
JP¥3,116.67
+70.6%
28.5%JP¥4,900.00JP¥2,200.00JP¥2,081.006
Apr ’24JP¥1,879.00
JP¥3,116.67
+65.9%
28.5%JP¥4,900.00JP¥2,200.00JP¥1,426.006
Mar ’24JP¥1,784.00
JP¥3,116.67
+74.7%
28.5%JP¥4,900.00JP¥2,200.00JP¥1,533.506
Feb ’24JP¥1,973.00
JP¥3,216.67
+63.0%
31.6%JP¥4,900.00JP¥2,000.00JP¥1,256.006
Jan ’24JP¥2,077.00
JP¥3,216.67
+54.9%
31.6%JP¥4,900.00JP¥2,000.00JP¥1,486.506
Dec ’23JP¥1,723.00
JP¥3,216.67
+86.7%
31.6%JP¥4,900.00JP¥2,000.00JP¥1,264.006
Nov ’23JP¥1,605.00
JP¥3,416.67
+112.9%
31.9%JP¥4,900.00JP¥2,000.00JP¥1,126.006

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,091.50

7D

-1.8%

1Y

-10.0%

Tsumura

JP¥373.7b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,921.00

7D

-0.7%

1Y

81.2%

ASKA Pharmaceutical HoldingsLtd

JP¥57.8b

Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan.

4886

JP¥2,037.00

7D

-4.1%

1Y

14.8%